A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.

NCT00295763 | Completed Phase 3

• 1 other identifier: THYR01605
• Study Type: interventional
• Target: 61
• Locations: 5 countries
• Sites: 9

Brief Summary

Patients diagnosed with thyroid cancer are commonly treated with surgery to remove their thyroid gland followed by radioiodine ablation to destroy any remaining parts of the thyroid gland that may have been missed during surgery. It is thought that ablation with radioiodine destroys normal remaining thyroid tissue as well as cancerous cells either in the thyroid area or at other sites. Following successful treatment, patients are then monitored by their physicians at regular intervals with testing to detect any recurrence of thyroid cancer throughout the body. If thyroid cells are detected by these follow up tests, the physician will decide the best method to re-treat the patient. In 2001-2003 Genzyme conducted a clinical study to test if Thyrogen® can be used to accomplish radioiodine ablation treatment. This study aimed to determine that the success rates of radioiodine ablation were comparable when patients were prepared for ablation with Thyrogen® while being maintained on their normal thyroid hormone therapy, or, alternatively, by thyroid hormone withdrawal. Thyroid hormone withdrawal commonly causes uncomfortable side effects for patients, and these might be avoided by the use of Thyrogen. Eight months after the initial Thyrogen plus radioiodine treatment to achieve ablation, all patients in both groups were given Thyrogen® to test for any remaining thyroid tissue. The results of this testing showed that all patients (in both groups) had successfully achieved remnant ablation and had no detectable thyroid tissue remaining. In order to confirm these remnant ablation results we will conduct follow up testing in this study for all patients that were enrolled in the previous study and we also will determine if their thyroid cancer has recurred. Only patients who completed this previous Thyrogen ablation study are eligible for entry into this study.

Conditions

Differentiated Thyroid Cancer

Keywords

papillary thyroid cancer; follicular thyroid cancer; recombinant human TSH; Thyrogen; thyroid stimulating hormone; thyroid remnant ablation; radioiodine

Outcome Measures

Primary Outcomes (4)

• To confirm the status of thyroid remnant ablation by using Thyrogen stimulated radioiodine whole body scans (WBS) in patients previously treated in THYR-008-00.

  Duration of study

• To learn if there was recurrence of thyroid cancer in any of the patients previously treated in the THYR-008-00 study.

  Duration of study

• To assess Thyrogen-stimulated serum Tg measurements in patients previously treated in the THYR-008-00 study.

  Duration of study

• To assess safety information on repeat exposure to Thyrogen in patients previously treated in the THYR-008-00 study.

  Duration of study

Study Arms (1)

1

OTHER

Drug: Thyrogen (thyrotropin alfa for injection)

Interventions

Thyrogen (thyrotropin alfa for injection) DRUG

No reference therapy was given. All patients in this follow-up study received Thyrogen. Thyrogen 0.9 mg was administered intramuscularly (IM) in the buttock on 2 consecutive days. For WBS and static neck imaging, each patient received 4 mCi (148 MBq) ± 0.4 mCi 131I PO.

1

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Committed to follow the protocol requirements, as evidenced by providing written informed consent before any study-related procedures are performed and within 28 days prior to Day 1;
• Completed the THYR-008-00 study;
• A negative serum pregnancy test within 8 days prior to the start of the week during which the patient will receive Thyrogen and radioiodine (required for all pre-menopausal women of child bearing potential, with menopause defined as age \>50 years with \>2 years without a menstrual period)

You may not qualify if:

• Patients who are currently taking amiodarone or other prescribed iodine-containing medication;
• Patients who received iodine-containing X-ray contrast material within the prior 3 months;
• Women of child-bearing potential, unless confirmed to have a negative pregnancy test prior to dosing;
• Women who are pregnant or lactating;
• Patients who are currently participating in another investigational drug study or who have participated in such a study within 30 days of their enrollment in this study;
• Patients with schedule or travel plans that prevent the completion of all required visits;
• The patient who by mistake received only one-half the intended dose of Thyrogen during THYR-008-00 (Patient 209);
• The patient in THYR-008-00 who was found to have lung metastases on her post therapy scan (Patient 204);
• A concurrent major medical disorder (e.g., documented significant cardiac disease, debilitating cardiopulmonary disease, advanced renal failure, advanced liver disease, advanced pulmonary disease, or advanced cerebral vascular disorder) that may have an impact on the capability of the patient to adequately comply with the requirements of this study.

Sponsors & Collaborators

• Genzyme, a Sanofi Company: lead

Study Sites (9)

University of Colorado Health Sciences Centre

Aurora, Colorado, 80010, United States

Location

Johns Hopkins University

Baltimore, Maryland, 21287, United States

Location

Ohio State University

Columbus, Ohio, 43210, United States

Location

MD Anderson Cancer Centre

Houston, Texas, 77030, United States

Location

LHRI Research Services

London, Ontario, N6A 4G5, Canada

Location

Centre Rene Huguenin

Saint-Cloud, 92210, France

Location

Institut Gustave Roussy

Villejuif, 94805, France

Location

University of Wurzburg

Würzburg, 97080, Germany

Location

University of Pisa

Pisa, 56124, Italy

Location

Related Publications (1)

• Elisei R, Schlumberger M, Driedger A, Reiners C, Kloos RT, Sherman SI, Haugen B, Corone C, Molinaro E, Grasso L, Leboulleux S, Rachinsky I, Luster M, Lassmann M, Busaidy NL, Wahl RL, Pacini F, Cho SY, Magner J, Pinchera A, Ladenson PW. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab. 2009 Nov;94(11):4171-9. doi: 10.1210/jc.2009-0869. Epub 2009 Oct 22.

  PMID: 19850694 DERIVED

MeSH Terms

Conditions

Thyroid Cancer, Papillary; Adenocarcinoma, Follicular

Interventions

Thyrotropin Alfa; Injections

Condition Hierarchy (Ancestors)

Adenocarcinoma, Papillary; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Thyroid Neoplasms; Endocrine Gland Neoplasms; Neoplasms by Site; Head and Neck Neoplasms; Endocrine System Diseases; Thyroid Diseases

Intervention Hierarchy (Ancestors)

Thyrotropin; Pituitary Hormones, Anterior; Pituitary Hormones; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Drug Administration Routes; Drug Therapy; Therapeutics

Study Officials

• Medical Monitor

  Genzyme, a Sanofi Company

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: February 22, 2006
• First Posted: February 24, 2006
• Study Start: May 1, 2006
• Primary Completion: July 1, 2006
• Study Completion: September 1, 2006
• Last Updated: March 18, 2015

Record last verified: 2015-03

Locations

CA (1); US (4); DE (1); FR (2); IT (1)